Soluble epoxide hydrolase (sEH) converts epoxides to their corresponding diols. Inhibitors of sEH have anti-inflammatory, anti-hypertensive, neuroprotective, and cardioprotective effects. trans-AUCB is a very potent inhibitor of sEH (IC50 = 0.5 nM). It displays high oral bioavailability for doses ranging from 0.01 to 1 mg/kg. Dual inhibition of COX-2 and sEH, by celecoxib and trans-AUCB, suppresses tumor angiogenesis, inhibiting tumor growth and metastasis in a Lewis lung carcinoma model in mice.
